{
    "clinical_study": {
        "@rank": "47042", 
        "arm_group": [
            {
                "arm_group_label": "0.3 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "IV infusion of migalastat HCl or placebo"
            }, 
            {
                "arm_group_label": "1 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "IV infusion of migalastat HCl or placebo"
            }, 
            {
                "arm_group_label": "10 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "IV infusion of migalastat HCl or placebo"
            }, 
            {
                "arm_group_label": "150 mg IV", 
                "arm_group_type": "Experimental", 
                "description": "150 mg single IV infusion"
            }, 
            {
                "arm_group_label": "150 mg oral", 
                "arm_group_type": "Experimental", 
                "description": "150 mg single oral dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of\n      IV migalastat HCl alone and to determine absolute bioavailability for oral migalastat HCl as\n      compared to IV administered migalastat HCl in healthy volunteers. The data from this study\n      will help us understand how migalastat works in the body and will help us determine what\n      would be an effective dose in future studies with migalastat hydrochloride."
        }, 
        "brief_title": "A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Fabry Disease", 
        "condition_browse": {
            "mesh_term": "Fabry Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females between 18 and 45 years of age.\n\n          -  Body weight range \u2265 50 kg \u2264 100 kg and BMI within the range 18.5 - 29.9 kg/m2.\n\n          -  Healthy as determined by a responsible and experienced physician, based on a medial\n             evaluation.\n\n          -  Male and female subjects of childbearing potential agree to adhere to the\n             contraception requirements.\n\n          -  Capable of giving written informed consent.\n\n        Exclusion Criteria:\n\n          -  History of sensitivity to migalastat HCl or related iminosugars (eg, miglitol,\n             miglustat), or other significant drug allergy.\n\n          -  Past medical history, or physical examination findings, of clinically significant\n             abnormalities that may put the subject at risk or interfere with outcome variables.\n\n          -  Positive pre-study drug/alcohol screen.\n\n          -  Pregnant or lactating females.\n\n          -  The subject has participated in a clinical trial and has received an investigational\n             product within 60 days prior to the first dosing day in the current study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02082327", 
            "org_study_id": "AT1001-018", 
            "secondary_id": "2013-005553-75"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "0.3 mg/kg", 
                    "1 mg/kg", 
                    "10 mg/kg", 
                    "150 mg IV", 
                    "150 mg oral"
                ], 
                "intervention_name": "IV migalastat HCl", 
                "intervention_type": "Drug", 
                "other_name": "AT1001"
            }, 
            {
                "arm_group_label": [
                    "0.3 mg/kg", 
                    "1 mg/kg", 
                    "10 mg/kg"
                ], 
                "intervention_name": "IV placebo", 
                "intervention_type": "Drug", 
                "other_name": "Sodium Chloride 0.9%"
            }, 
            {
                "arm_group_label": [
                    "150 mg IV", 
                    "150 mg oral"
                ], 
                "intervention_name": "oral migalastat HCl", 
                "intervention_type": "Drug", 
                "other_name": "AT1001"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Fabry Disease", 
            "Fabry", 
            "Lysosomal storage disorders", 
            "LSD", 
            "Amicus", 
            "migalastat HCl", 
            "migalastat", 
            "AT1001"
        ], 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "contact": {
                "email": "SchuilengaPetra@PRAIntl.com", 
                "last_name": "Petra Schuilenga-Hut, PhD", 
                "phone": "31504022693"
            }, 
            "facility": {
                "address": {
                    "city": "Groningen", 
                    "country": "Netherlands", 
                    "zip": "9713 GZ"
                }, 
                "name": "PRA International"
            }, 
            "investigator": {
                "last_name": "Nada Al Kotbi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers With an Open-Label, Randomized, Two-Way Crossover Arm", 
        "overall_official": {
            "affiliation": "Amicus Therapeutics", 
            "last_name": "Medical Monitor Clinical Research", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To investigate the effect on the body of migalastat following a single 2 hour IV  infusion in healthy subjects.", 
                "measure": "Plasma pharmacokinetics of migalastat", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 1, 1.5, 2.0, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48"
            }, 
            {
                "description": "Adverse events, clinical laboratory test values, vital signs, ECG, physical examinations", 
                "measure": "Safety and tolerability of migalastat", 
                "safety_issue": "Yes", 
                "time_frame": "48 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02082327"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess the dose proportionality of migalastat following a single 2 hour IV infusion", 
                "measure": "Plasma pharmacokinetics of migalastat", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25, 0.5, 1, 1.5, 2.0, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48"
            }, 
            {
                "description": "To estimate the urinary excretion of unchanged migalastat following a single 2 hour IV infusion in healthy subjects", 
                "measure": "Urinary pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Pre dose, between 0-6, 6-12 and 12-24 hours after start of infusion"
            }
        ], 
        "source": "Amicus Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amicus Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}